Search

Your search keyword '"Kim, Lilianne"' showing total 47 results
Start Over Author "Kim, Lilianne" Publication Year Range Last 50 years
47 results on '"Kim, Lilianne"'

4. Outcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-Onset and Adult-Onset Disease

Author

Rosh, Joel R, primary, Turner, Dan, additional, Hyams, Jeffrey S, additional, Dubinsky, Marla, additional, Griffiths, Anne M, additional, Cohen, Stanley A, additional, Lo, Kim Hung, additional, Kim, Lilianne, additional, Volger, Sheri, additional, Zhang, Renping, additional, Strauss, Richard, additional, and Conklin, Laurie S, additional

Published
2024
Full Text
View/download PDF

6. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis

Author

Telesco, Shannon E., Brodmerkel, Carrie, Zhang, Hongyan, Kim, Lilianne (Lee-Lian), Johanns, Jewel, Mazumder, Abhijit, Li, Katherine, Baribaud, Frédéric, Curran, Mark, Strauss, Richard, Paxson, Bethany, Plevy, Scott, Davison, Timothy, Knight, Laura, Dibben, Sian, Schreiber, Stefan, Sandborn, William, Rutgeerts, Paul, Siegel, Corey A., Reinisch, Walter, and Greenbaum, Linda E.

Published
2018
Full Text
View/download PDF

8. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial

Author

Brunner, Hermine I, Ruperto, Nicolino, Tzaribachev, Nikolay, Horneff, Gerd, Chasnyk, Vyacheslav G, Panaviene, Violeta, Abud-Mendoza, Carlos, Reiff, Andreas, Alexeeva, Ekaterina, Rubio-Pérez, Nadina, Keltsev, Vladimir, Kingsbury, Daniel J, del Rocio Maldonado Velázquez, Maria, Nikishina, Irina, Silverman, Earl D, Joos, Rik, Smolewska, Elzbieta, Bandeira, Márcia, Minden, Kirsten, van Royen-Kerkhof, Annet, Emminger, Wolfgang, Foeldvari, Ivan, Lauwerys, Bernard R, Sztajnbok, Flavio, Gilmer, Keith E, Xu, Zhenhua, Leu, Jocelyn H, Kim, Lilianne, Lamberth, Sarah L, Loza, Matthew J, Lovell, Daniel J, and Martini, Alberto

Published
2018
Full Text
View/download PDF

16. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1□year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial

Author

Weinblatt, Michael E, Westhovens, Rene, Mendelsohn, Alan M, Kim, Lilianne, Lo, Kim Hung, Sheng, Shihong, Noonan, Lenore, Lu, Jiandong, Xu, Zhenhua, Leu, Jocelyn, Baker, Daniel, and Bingham, Clifton O

Published
2014
Full Text
View/download PDF

18. A148: A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results

Author

Brunner, Hermine, Ruperto, N., Tzaribachev, N., Horneff, G., Wouters, C., Panaviene, V., Chasnyk, V., Abud-Mendoza, C., Cuttica, R., Reiff, A., Maldonado-Velázquez, M., Rubio-Perez, N., Alexeeva, Ekaterina, Joos, R., Keltsev, V., Nasonov, E., Kingsbury, D., Bandeira, M., Silverman, E., Weller-Heinemann, F., van Royen-Kerkhof, A., Mendelsohn, Alan, Kim, Lilianne, Lovell, D., and Martini, A.

Published
2014
Full Text
View/download PDF

23. Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study

Author

Mease, Philip, primary, Elaine Husni, M., additional, Chakravarty, Soumya D., additional, Kafka, Shelly, additional, Parenti, Dennis, additional, Kim, Lilianne, additional, Hung Lo, Kim, additional, Hsia, Elizabeth C., additional, and Kavanaugh, Arthur, additional

Published
2020
Full Text
View/download PDF

24. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial

Author

Reveille, John D., primary, Hwang, Mark C., additional, Danve, Abhijeet, additional, Kafka, Shelly, additional, Peterson, Steven, additional, Lo, Kim Hung, additional, Kim, Lilianne, additional, Hsia, Elizabeth C., additional, Chan, Eric K. H., additional, and Deodhar, Atul, additional

Published
2020
Full Text
View/download PDF

27. AB0754 CLINICALLY MEANINGFUL IMPROVEMENT IN SKIN AND NAIL PSORIASIS IN BIO-NAÏVE ACTIVE PSORIATIC ARTHRITIS PATIENTS TREATED WITH INTRAVENOUS GOLIMUMAB: RESULTS THROUGH WEEK 52 FROM A PHASE-3 STUDY

Author

Elaine Husni, M, primary, Mease, Philip J., additional, Chakravarty, Soumya D., additional, Kafka, Shelly, additional, Harrison, Diane D., additional, Parenti, Dennis, additional, Kim, Lilianne, additional, Lo, Kim Hung, additional, Hsia, Elizabeth C., additional, and Kavanaugh, Arthur, additional

Published
2019
Full Text
View/download PDF

28. Case Reports1. A Late Presentation of Loeys-Dietz Syndrome: Beware of TGFβ Receptor Mutations in Benign Joint Hypermobility

Author

Mehta, Puja, Holder, Susan, Fisher, Benjamin, Vincent, Tonia, Nadesalingam, Kavitha, Maciver, Helen, Shingler, Wendy, Bakshi, Jyoti, Hassan, Sadon, D'Cruz, David, Chan, Antoni, Litwic, Anna E., McCrae, Fiona, Seth, Rakhi, Nandagudi, Anupama, Jury, Elizabeth, Isenberg, David, Karjigi, Uma, Paul, Anupam, Rees, Frances, O'Dowd, Emma, Kinnear, William, Johnson, Simon, Lanyon, Peter, Stevens, Richard, Narayan, Nehal, Marguerie, Christopher, Robinson, Helena, Ffolkes, Lorrette, Worsnop, Fiona, Ostlere, Lucy, Kiely, Patrick, Dharmapalaiah, Chethana, Hassan, Nada, Bharadwaj, Anurag, Skibinska, Malgorzata, Gendi, Nagui, Davies, Emma J., Akil, Mohammed, Kilding, Rachael, Ramachandran Nair, Jagdish, Walsh, Maeve, Farrar, Wendy, Thompson, Robert N., Borukhson, Liubov, McFadyen, Charles, Singh, Deepwant, Rajagopal, Vivek, Chan, Angela Marie L., Wearn Koh, Li, Christie, Jennifer D., Croot, Lorraine, Gayed, Mary, Disney, Benjamin, Singhal, Saket, Grindulis, Karl, Reynolds, Timothy D., Conway, Katie, Williams, Debbie, Quin, John, Dean, Gillian, Churchill, Duncan, Walker-Bone, Karen E., Goff, Iain, Reynolds, Gary, Grove, Matthew, Patel, Priya, Lazarus, Mark N., Roncaroli, Frederico, Gabriel, Carolyn, Kinderlerer, Anne R., Nikiphorou, Elena, Hall, Frances C., Bruce, Ellen, Gray, Leanne, Krutikov, Maria, Wig, Surabhi, Bruce, Ian, D'Agostino, Maria A., Wakefield, Richard, Berner Hammer, Hilde, Vittecoq, Olivier, Galeazzi, Mauro, Balint, Peter, Filippucci, Emilio, Moller, Ingrid, Iagnocco, Annamaria, Naredo, Esperanza, Ostergaard, Mikkel, Gaillez, Corine, Kerselaers, Wendy, Van Holder, Karina, Le Bars, Manuela, Stone, Millicent A., Williams, Francis, Wolber, Lisa, Karppinen, Jaro, Maatta, Juhani, Thompson, Ben, Atchia, Ismael, Lorenzi, Alice, Raftery, Graham, Platt, Phil, Platt, Philip N., Pratt, Arthur, Turmezei, Thomas D., Treece, Graham M., Gee, Andrew H., Poole, Kenneth E., Chandratre, Priyanka N., Roddy, Edward, Clarson, Lorna, Richardson, Jane, Hider, Samantha, Mallen, Christian, Lieberman, Abigail, Prouse, Peter J., Mahendran, Prini, Samarawickrama, Amanda, Ottery, Faith D., Yood, Robert, Wolfson, Marsha, Ang, Andrea, Riches, Philip, Thomson, Janet, Nuki, George, Humphreys, Jennifer, Verstappen, Suzanne M., Chipping, Jacqueline, Hyrich, Kimme, Marshall, Tarnya, Symmons, Deborah P., Roy, Matthew, Kirwan, John R., Marshall, Robert W., Matcham, Faith, Scott, Ian C., Rayner, Lauren, Hotopf, Matthew, Kingsley, Gabrielle H., Scott, David L., Steer, Sophia, Ma, Margaret H., Dahanayake, Chanaka, Kingsley, Gabrielle, Cope, Andrew, Wernham, Aaron, Ward, Lorna, Carruthers, David, Deeming, Alison, Buckley, Christopher, Raza, Karim, De Pablo, Paola, Carpenter, Lewis, Jayakumar, Keeranur, Solymossy, Csilla, Dixey, Josh, Young, Adam, Singh, Animesh, Penn, Henry, Ellerby, Nicholas, Mattey, Derek L., Packham, Jonathan, Dawes, Peter, Hider, Samantha L., Ng, Nora, Humby, Frances, Bombardieri, Michele, Kelly, Stephen, Di Cicco, Maria, Dadoun, Sabrina, Hands, Rebecca, Rocher, Vidalba, Kidd, Bruce, Pyne, Dev, Pitzalis, Costantino, Poore, Sophie, Hutchinson, David, Low, Audrey, Lunt, Mark, Mercer, Louise, Galloway, James, Davies, Rebecca, Watson, Kath, Dixon, Will, Symmons, Deborah, Watson, Kath D., Dixon, William G., Hyrich, Kimme L., Malik, Saadia P., Kelly, Clive, Hamilton, Jennifer, Heycock, Carol, Saravanan, Vadivelu, Rynne, Martin, Harris, Helen E., Tweedie, Fiona, Skaparis, Yiannis, White, Marie, Scott, Nicola, Samson, Kay, Mercieca, Cecilia, Clarke, Shane, Warner, Alexander J., Verstappen, Suzanne, Chan, Esther, Woodhead, Felix A., Nisar, Mohamed, Arthanari, S., Dawson, Julie, Sathi, Nav, Ahmad, Yasmeen, Koduri, Gouri, Cumming, Jo, Stannett, Peter, Hull, Richard, Metsios, George, Stavropoulos Kalinoglou, Antonios, Veldhuijzen van Zanten, Jet J., Nightingale, Peter, Koutedakis, Yiannis, Kitas, George D., Williams, Peter, Walsh, David, Perry, Elizabeth, de-Soyza, Anthony, Moullaali, Thomas, Eggleton, Paul, Stavropoulos-Kalinoglou, Antonios, Sandoo, Aamer, de Pablo, Paola, Maggs, Fiona, Faizal, Abdul, Pugh, Mark, Jobanputra, Paresh, Kehoe, Oksana, Cartwright, Alison, Askari, Ayman, El Haj, Alicia, Middleton, Jim, Aynsley, Sarah, Hardy, Jacob, Veale, Douglas, Fearon, Ursula, Wilson, Gerry, Muthana, Munitta, Fossati, G., Healy, L., Nesbitt, A., Becerra, Elena, Leandro, Maria J., De La Torre, Inmaculada, Cambridge, Geraldine, Nelson, P. N., Roden, D., Shaw, M., Davari Ejtehadi, Hora, Nevill, A., Freimanis, G., Hooley, P., Bowman, S., Alavi, A., Axford, J., Veitch, A. M., Tugnet, N., Rylance, P. B., Hawtree, Sarah, Mark Wilkinson, J., Wilson, Anthony G., Woon Kam, Ngar, Filter, Andrew, Croft, Adam P., Naylor, Amy, Zimmermann, Birgit, Hardie, Debbie, Desanti, Guillaume, Jaurez, Maria, Muller-Ladner, Ulf, Filer, Andrew, Neumann, Elena, Movahedi, Mohammad, Ray, David W., Burmester, Gerd R., Matucci-Cerinic, Marco, Navarro-Blasco, Francisco, Kary, Sonja, Unnebrink, Kristina, Kupper, Hartmut, Mukherjee, Sandeep, Cornell, Patricia, Richards, Selwyn, Rahmeh, Fouz, Thompson, Paul W., Westlake, Sarah L., Javaid, Muhammad K., Batra, Rajbir, Chana, Jasroop, Round, Gemma, Judge, Andrew, Taylor, Peter, Patel, Sanjeev, Cooper, Cyrus, Ravindran, Vinod, Bingham, Clifton O., Weinblatt, Michael E., Mendelsohn, Alan, Kim, Lilianne, Mack, Michael, Lu, Jiandong, Baker, Daniel, Westhovens, Rene, Hewitt, Jamie, Han, Chenglong, Keystone, Edward C., Fleischmann, Roy, Smolen, Josef, Emery, Paul, Genovese, Mark, Doyle, Mittie, Hsia, Elizabeth C., Hart, Jennifer C., Harland, Dave, Gibbons, Carl, Pang, Hok, Huertas, Catherine, Diamantopoulos, Alex, Dejonckheere, Fred, Clowse, M., Wolf, D., Stach, C., Kosutic, G., Williams, S., Terpstra, I., Mahadevan, U., Ferraccioli, G., Samborski, W., Berenbaum, F., Davies, O., Koetse, W., Bennett, B., Burkhardt, H., Luijtens, K., van der Heijde, Desiree, Mariette, X., van Vollenhoven, Ronald F., Bykerk, V., de Longueville, M., Arendt, C., Cush, J., Khan, Afsha, Maclaren, Zoe, Dubash, Sayam, Chalam, Venkat C., Sheeran, Tom, Price, Tom, Baskar, Sangeetha, Mulherin, Diarmuid, Molloy, Cauline, Keay, Fiona, Heritage, Caroline, Douglas, Barbara, Schiff, Michael H., Khanna, Dinesh, Furst, Daniel E., Maldonado, Michael A., Li, Wanying, Sasso, Eric H., Emerling, Daniel, Cavet, Guy, Ford, Kerri, Mackenzie-Green, Bronwen, Collins, David, Price, Elizabeth, Williamson, Lyn, Golla, Janardhana, Vagadia, Vipul, Morrison, Elaine, Tierney, Ann, Wilson, Hilary, Hunter, John, Reddy, Venkat, Moore, Samantha, Ehrenstein, Michael, Benson, Claire, Wray, Maria, Cairns, Andrew, Wright, Gary, Pendleton, Adrian, McHenry, Michelle, Taggart, Allister, Bell, Aubrey, Bosworth, Ailsa, Cox, Maureen, Johnston, Graeme, Shah, Preeti, O'Brien, Anne, Jones, Peter, Sargeant, Ify, Bukhari, Marwan, Nusslein, Hubert, Alten, Rieke, Lorenz, Hannes M., Boumpas, Dimitrios, Nurmohamed, Michael T., Bensen, William, Peter, Hans-Hartmut, Rainer, Franz, Pavelka, Karel, Chartier, Melanie, Poncet, Coralie, Rauch, Christiane, Lempp, Heidi, Hofmann, Darija, Adu, Aderonke, Congreve, Carron, Dobson, Joanne, Rose, Diana, Simpson, Carol, Wykes, Til, Ibrahim, Fowzia, Schiff, Michael, Nash, Peter, Durez, Patrick, Kaine, Jeffrey, Delaet, Ingrid, Kelly, Sheila, Maldonado, Michael, Patel, Salil, Jones, Graeme, Sebba, Anthony, Lepley, Denise, Devenport, Jenny, Bernasconi, Corrado, Smart, Devi, Mpofu, Chiedzo, Gomez-Reino, Juan J., Verma, Inderjeet, Kaur, Jaspreet, Syngle, Ashit, Krishan, Pawan, Vohra, Kanchan, Kaur, Ladbans, Garg, Nidhi, Chhabara, Monica, Gibson, Kellie, Woodburn, James, Telfer, Scott, Buckley, Felicity, Finckh, Axel, Huizinga, Tom W., Jansen, Jeroen P., Rubbert-Roth, Andrea, Scali, Juan J., Kremer, Joel M., Pitts, Laura, Vernon, Emma, Sharif, Mohammed I., Das, Sudipto, Helliwell, Philip, Sokoll, Katharina, and Vital, Edward M.

Subjects
cardiovascular system
Abstract

Background: Thoracic aortic aneurysms (TAA) and dissections are not uncommon causes of sudden death in young adults. Loeys-Dietz syndrome (LDS) is a rare, recently described, autosomal dominant, connective tissue disease characterized by aggressive arterial aneurysms, resulting from mutations in the transforming growth factor beta (TGFβ) receptor genes TGFBR1 and TGFBR2. Mean age at death is 26.1 years, most often due to aortic dissection. We report an unusually late presentation of LDS, diagnosed following elective surgery in a female with a long history of joint hypermobility. Methods: A 51-year-old Caucasian lady complained of chest pain and headache following a dural leak from spinal anaesthesia for an elective ankle arthroscopy. CT scan and echocardiography demonstrated a dilated aortic root and significant aortic regurgitation. MRA demonstrated aortic tortuosity, an infrarenal aortic aneurysm and aneurysms in the left renal and right internal mammary arteries. She underwent aortic root repair and aortic valve replacement. She had a background of long-standing joint pains secondary to hypermobility, easy bruising, unusual fracture susceptibility and mild bronchiectasis. She had one healthy child age 32, after which she suffered a uterine prolapse. Examination revealed mild Marfanoid features. Uvula, skin and ophthalmological examination was normal. Results: Fibrillin-1 testing for Marfan syndrome (MFS) was negative. Detection of a c.1270G > C (p.Gly424Arg) TGFBR2 mutation confirmed the diagnosis of LDS. Losartan was started for vascular protection. Conclusions: LDS is a severe inherited vasculopathy that usually presents in childhood. It is characterized by aortic root dilatation and ascending aneurysms. There is a higher risk of aortic dissection compared with MFS. Clinical features overlap with MFS and Ehlers Danlos syndrome Type IV, but differentiating dysmorphogenic features include ocular hypertelorism, bifid uvula and cleft palate. Echocardiography and MRA or CT scanning from head to pelvis is recommended to establish the extent of vascular involvement. Management involves early surgical intervention, including early valve-sparing aortic root replacement, genetic counselling and close monitoring in pregnancy. Despite being caused by loss of function mutations in either TGFβ receptor, paradoxical activation of TGFβ signalling is seen, suggesting that TGFβ antagonism may confer disease modifying effects similar to those observed in MFS. TGFβ antagonism can be achieved with angiotensin antagonists, such as Losartan, which is able to delay aortic aneurysm development in preclinical models and in patients with MFS. Our case emphasizes the importance of timely recognition of vasculopathy syndromes in patients with hypermobility and the need for early surgical intervention. It also highlights their heterogeneity and the potential for late presentation. Disclosures: The authors have declared no conflicts of interest

Published
2017

31. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial

Author

Immuno/reuma patientenzorg, Infection & Immunity, Child Health, Reumatologie patientenzorg, UMC Utrecht, Brunner, Hermine I, Ruperto, Nicolino, Tzaribachev, Nikolay, Horneff, Gerd, Chasnyk, Vyacheslav G., Panaviene, Violeta Vladislava, Abud-Mendoza, Carlos, Reiff, Andreas, Alexeeva, Ekaterina, Rubio-Pérez, Nadina, Keltsev, Vladimir, Kingsbury, Daniel J., Del Rocio Maldonado Velázquez, Maria, Nikishina, Irina, Silverman, Earl D., Joos, Rik, Smolewska, Elzbieta, Bandeira, Márcia, Minden, Kirsten, van Royen-Kerkhof, Annet, Emminger, Wolfgang, Foeldvari, Ivan, Lauwerys, Bernard R., Sztajnbok, Flavio, Gilmer, Keith E., Xu, Zhenhua, Leu, Jocelyn H., Kim, Lilianne, Lamberth, Sarah L., Loza, Matthew J., Lovell, Daniel J., Martini, Alberto, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG), Immuno/reuma patientenzorg, Infection & Immunity, Child Health, Reumatologie patientenzorg, UMC Utrecht, Brunner, Hermine I, Ruperto, Nicolino, Tzaribachev, Nikolay, Horneff, Gerd, Chasnyk, Vyacheslav G., Panaviene, Violeta Vladislava, Abud-Mendoza, Carlos, Reiff, Andreas, Alexeeva, Ekaterina, Rubio-Pérez, Nadina, Keltsev, Vladimir, Kingsbury, Daniel J., Del Rocio Maldonado Velázquez, Maria, Nikishina, Irina, Silverman, Earl D., Joos, Rik, Smolewska, Elzbieta, Bandeira, Márcia, Minden, Kirsten, van Royen-Kerkhof, Annet, Emminger, Wolfgang, Foeldvari, Ivan, Lauwerys, Bernard R., Sztajnbok, Flavio, Gilmer, Keith E., Xu, Zhenhua, Leu, Jocelyn H., Kim, Lilianne, Lamberth, Sarah L., Loza, Matthew J., Lovell, Daniel J., Martini, Alberto, and Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)

Published
2018

32. Multizentrische, doppelblinde, randomisierte Studie von Golimumab bei pädiatrischen Patienten mit aktiver pJIA trotz Methotrexat: Ergebnisse nach 48 Wochen

Author

Brunner, Hermine, Horneff, Gerd, Ruperto, Nicola, Tzaribachev, Nikolay, Wouters, Carine, Chasnyk, Vyacheslav, Cuttica, Ruben, Keltsev, V., Nasonov, Evgeny, Kingsbury, D., Weller-Heinemann, Frank, Lovell, Daniel J., Martini, Alberto, Panaviene, Violeta Vladislava, Abud Mendoza, Carlos, Reiff, Andreas, Alexeeva, Ekaterina, Joos, Rik, Bandeira, Márcia, Silverman, Earl, Van Royen-Kerkhof, Annet, Kim, Lilianne, and Rubio-Perez, Nadina

Subjects
ddc: 610, randomisiert, doppelblind, 610 Medical sciences, Medicine, klinische Remission, ACR30-Ansprechen, Golimumab, juvenile idiopathische Arthritis
Abstract

Einleitung: Beurteilung der Wirksamkeit und Sicherheit von Golimumab (GLM) bei pädiatrischen Patienten (2-17 Jahre) mit aktiver polyartikulärer juveniler idiopathischer Arthritis (pJIA) trotz mindestens 3-monatiger MTX-Therapie. Methoden: GO-KIDS war eine 3-phasige (P1: Wo0-16, P2: Wo16-48,[zum vollständigen Text gelangen Sie über die oben angegebene URL], 44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2016

34. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial

Author

Brunner, Hermine I, primary, Ruperto, Nicolino, additional, Tzaribachev, Nikolay, additional, Horneff, Gerd, additional, Chasnyk, Vyacheslav G, additional, Panaviene, Violeta, additional, Abud-Mendoza, Carlos, additional, Reiff, Andreas, additional, Alexeeva, Ekaterina, additional, Rubio-Pérez, Nadina, additional, Keltsev, Vladimir, additional, Kingsbury, Daniel J, additional, del Rocio Maldonado Velázquez, Maria, additional, Nikishina, Irina, additional, Silverman, Earl D, additional, Joos, Rik, additional, Smolewska, Elzbieta, additional, Bandeira, Márcia, additional, Minden, Kirsten, additional, van Royen-Kerkhof, Annet, additional, Emminger, Wolfgang, additional, Foeldvari, Ivan, additional, Lauwerys, Bernard R, additional, Sztajnbok, Flavio, additional, Gilmer, Keith E, additional, Xu, Zhenhua, additional, Leu, Jocelyn H, additional, Kim, Lilianne, additional, Lamberth, Sarah L, additional, Loza, Matthew J, additional, Lovell, Daniel J, additional, and Martini, Alberto, additional

Published
2017
Full Text
View/download PDF

35. Prediction of Non-Response to Anti-Tnf Therapy in Ulcerative Colitis: Implications for Patient Stratification for IBD Trials and Novel Treatment Paradigms

Author

Telesco, Shannon, primary, Greenbaum, Linda, additional, Zhang, Hongyan, additional, Mazumder, Ron, additional, Kim, Lilianne, additional, Johanns, Jewel, additional, Imm, Paul, additional, Paxson, Bethany, additional, Curran, Mark, additional, Baribaud, Fred, additional, Li, Katherine, additional, Zoka, Ramineh, additional, and Brodmerkel, Carrie, additional

Published
2017
Full Text
View/download PDF

36. Maintenance of clinical and radiographic benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: Week-112 efficacy and safety results of the open-label long-term extension of the GO-FURTHER trial

Author

Bingham, Clifton O, Mendelsohn, Alan M, Kim, Lilianne, Xu, Zhenhua, Leu, Jocelyn, Han, Chenglong, Hung Lo, Kim, Westhovens, Rene, Weinblatt, Michael E, and on behalf of the GO-FURTHER Investigators

Subjects
medicine.medical_specialty, Time Factors, Placebo-controlled study, Rheumatoid Arthritis, Blood Sedimentation, Placebo, Drug Administration Schedule, law.invention, Etanercept, Arthritis, Rheumatoid, Disability Evaluation, Rheumatology, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Surveys and Questionnaires, medicine, Humans, Adverse effect, Cross-Over Studies, business.industry, Antibodies, Monoclonal, Recovery of Function, medicine.disease, Crossover study, Golimumab, Surgery, Radiography, C-Reactive Protein, Methotrexate, Treatment Outcome, Rheumatoid arthritis, Antirheumatic Agents, Quality of Life, Administration, Intravenous, Drug Therapy, Combination, Inflammation Mediators, business, Biomarkers, medicine.drug
Abstract

Objective To evaluate the safety, efficacy, pharmacokinetics, immunogenicity, and radiographic progression through 2 years of treatment with intravenous (IV) golimumab plus methotrexate (MTX) in an open-label extension of a phase III trial of patients with active rheumatoid arthritis (RA) despite MTX therapy. Methods In the phase III, double-blind, randomized, placebo-controlled GO-FURTHER trial, 592 patients with active RA were randomized (2:1) to intravenous golimumab 2 mg/kg plus MTX (Group 1) or placebo plus MTX (Group 2) at weeks 0 and 4, then every 8 weeks thereafter; placebo patients crossed over to golimumab at week 16 (early escape) or week 24 (crossover). The final golimumab infusion was at week 100. Assessments included American College of Rheumatology 20%, 50%, 70% (ACR20, ACR50, ACR70) response criteria, 28-joint count disease activity score using the C-reactive protein level (DAS28-CRP), physical function and quality of life measures, and changes in the modified Sharp/van der Heijde scores (SHS). Safety was monitored through week 112. Results In total, 486 patients (82.1%) continued treatment through week 100, and 68.1%, 43.8%, and 23.5% had an ACR20/50/70 response, respectively, at week 100. Clinical response and improvements in physical function and quality of life were generally maintained from week 24 through 2 years. Mean change from baseline to week 100 in SHS score was 0.74 in Group 1 and 2.10 in Group 2 (P = 0.005); progression from week 52 to week 100 was clinically insignificant in both groups. A total of 481 patients completed the safety followup through week 112; 79.1% had an adverse event, and 18.2% had a serious adverse event. Conclusion Clinical response to IV golimumab plus MTX was maintained through week 100. Radiographic progression following golimumab treatment was clinically insignificant between week 52 and week 100. No unexpected adverse events occurred through week 112, and the safety profile was consistent with anti–tumor necrosis factor therapy.

Published
2015

40. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial

Author

Weinblatt, Michael E, primary, Westhovens, Rene, additional, Mendelsohn, Alan M, additional, Kim, Lilianne, additional, Lo, Kim Hung, additional, Sheng, Shihong, additional, Noonan, Lenore, additional, Lu, Jiandong, additional, Xu, Zhenhua, additional, Leu, Jocelyn, additional, Baker, Daniel, additional, and Bingham, Clifton O, additional

Published
2013
Full Text
View/download PDF

41. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial

Author

Weinblatt, Michael E, primary, Bingham, Clifton O, additional, Mendelsohn, Alan M, additional, Kim, Lilianne, additional, Mack, Michael, additional, Lu, Jiandong, additional, Baker, Daniel, additional, and Westhovens, Rene, additional

Published
2012
Full Text
View/download PDF

43. Erratum: Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty‐eight–week efficacy and safety results of a phase III randomized, double‐blind, placebo‐controlled study

Author

Kremer, Joel, primary, Ritchlin, Christopher, additional, Mendelsohn, Alan, additional, Baker, Daniel, additional, Kim, Lilianne, additional, Xu, Zhenhua, additional, Han, John, additional, and Taylor, Peter, additional

Published
2010
Full Text
View/download PDF

44. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.

Author

Bingham, Clifton O., Mendelsohn, Alan M., Kim, Lilianne, Xu, Zhenhua, Leu, Jocelyn, Han, Chenglong, Lo, Kim Hung, Westhovens, Rene, Weinblatt, Michael E., Bingham, Clifton O 3rd, and GO-FURTHER Investigators

Subjects
ANTIRHEUMATIC agents, BLOOD sedimentation, C-reactive protein, COMBINATION drug therapy, CLINICAL trials, COMPARATIVE studies, CONVALESCENCE, CROSSOVER trials, FUNCTIONAL assessment, DRUG administration, INFLAMMATORY mediators, INTRAVENOUS therapy, RESEARCH methodology, MEDICAL cooperation, METHOTREXATE, MONOCLONAL antibodies, QUALITY of life, RESEARCH, RHEUMATOID arthritis, TIME, EVALUATION research, RANDOMIZED controlled trials, TREATMENT effectiveness, BLIND experiment
Abstract

Objective: To evaluate the safety, efficacy, pharmacokinetics, immunogenicity, and radiographic progression through 2 years of treatment with intravenous (IV) golimumab plus methotrexate (MTX) in an open-label extension of a phase III trial of patients with active rheumatoid arthritis (RA) despite MTX therapy.Methods: In the phase III, double-blind, randomized, placebo-controlled GO-FURTHER trial, 592 patients with active RA were randomized (2:1) to intravenous golimumab 2 mg/kg plus MTX (Group 1) or placebo plus MTX (Group 2) at weeks 0 and 4, then every 8 weeks thereafter; placebo patients crossed over to golimumab at week 16 (early escape) or week 24 (crossover). The final golimumab infusion was at week 100. Assessments included American College of Rheumatology 20%, 50%, 70% (ACR20, ACR50, ACR70) response criteria, 28-joint count disease activity score using the C-reactive protein level (DAS28-CRP), physical function and quality of life measures, and changes in the modified Sharp/van der Heijde scores (SHS). Safety was monitored through week 112.Results: In total, 486 patients (82.1%) continued treatment through week 100, and 68.1%, 43.8%, and 23.5% had an ACR20/50/70 response, respectively, at week 100. Clinical response and improvements in physical function and quality of life were generally maintained from week 24 through 2 years. Mean change from baseline to week 100 in SHS score was 0.74 in Group 1 and 2.10 in Group 2 (P = 0.005); progression from week 52 to week 100 was clinically insignificant in both groups. A total of 481 patients completed the safety followup through week 112; 79.1% had an adverse event, and 18.2% had a serious adverse event.Conclusion: Clinical response to IV golimumab plus MTX was maintained through week 100. Radiographic progression following golimumab treatment was clinically insignificant between week 52 and week 100. No unexpected adverse events occurred through week 112, and the safety profile was consistent with anti-tumor necrosis factor therapy. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

45. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial.

Author

Weinblatt, Michael E., Westhovens, Rene, Mendelsohn, Alan M., Kim, Lilianne, Kim Hung Lo, Shihong Sheng, Noonan, Lenore, Jiandong Lu, Zhenhua Xu, Leu, Jocelyn, Baker, Daniel, and Bingham, Clifton O.

Abstract

Objective Report on radiographic effects and maintenance of clinical benefit with intravenous golimumab 2 mg/kg+methotrexate (MTX) for up to week (wk) 52 in active rheumatoid arthritis (RA). Methods Patients (n=592) with active RA (≥6/66 swollen, ≥6/68 tender joints, C reactive protein (CRP) ≥1.0 mg/dL and positive for rheumatoid factor and/or anticyclic citrullinated protein antibody at screening) despite MTX ≥3 months (stable dose of 15-25 mg/week for ≥4 weeks) participated in this multicentre, international, randomised, double blind, placebo controlled, phase 3 study. Patients were randomised (2:1) to receive intravenous golimumab 2 mg/kg or placebo infusions at weeks 0 and 4 and then every 8 weeks; patients continued their stable MTX regimen. Placebo patients started golimumab 2 mg/kg at wk16 (early escape; <10% improvement in tender and swollen joints) or wk24 (crossover by design). Week 24 and wk52 radiographic (van der Heijde-Sharp (vdH-S) scores), clinical efficacy and safety data up to 1 year are reported here. Results Significant and rapid clinical improvement was observed up to wk24 of intravenous golimumab therapy. Golimumab+MTX treated patients demonstrated less radiographic progression than placebo treated patients at wk24 (vdH-S score mean change 0.03 vs 1.09; p<0.001) and wk52 (0.13 vs 1.22; p=0.001). Among patients with ≥20% improvement in the American College of Rheumatology response criteria or who achieved a 'good' or 'moderate' response according to the 28 joint Disease Activity Score employing CRP at wk24, approximately 80% maintained this response up until wk52. Through an average of 43.5 weeks of follow-up, 64.6% of patients receiving golimumab+MTX reported adverse events, most commonly non-serious infections. Conclusions In patients with active RA despite MTX, intravenous golimumab+MTX yielded significant inhibition of structural damage at wk24 and wk52, and sustained clinical improvement in signs and symptoms with no new safety signals up to 1 year. Clinicaltrialsgov NCT00973479, EudraCT 2008-006 064-11. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

46. Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a Phase 2, randomized, placebo-controlled study.

Author

Anders HJ, Chan TM, Sanchez-Guerrero J, Wofsy D, Bensley K, Kim L, Hung Lo K, Shu C, Shao J, Karyekar CS, and Diamond B

Abstract

Objective: Evaluate the efficacy and safety of guselkumab, an interleukin (IL)-23 inhibitor, in a Phase 2, multicentre, randomized, double-blind, placebo-controlled study of patients with active lupus nephritis (LN)., Methods: Adults (18-75 years) with active LN (Class III-IV proliferative nephritis [kidney biopsy] and urine protein-to-creatinine ratio [UPCR)] of ≥ 1 mg/mg despite standard-of-care therapy) were randomized (1:1; planned sample = 60) to receive intravenous infusions of guselkumab 400 mg or placebo at Weeks 0, 4, and 8, then subcutaneous injections (guselkumab 200 mg or placebo) at Week12 and every 4 weeks through Week48 in addition to their background therapy. The primary end point was achievement of ≥ 50% decrease in proteinuria from baseline at Week24. Major secondary endpoints (Week24) were achievement of complete renal response (CRR), sustained reduction in steroid dose (≤10 mg/day prednisone/equivalent) from Weeks 16-24, UPCR <0.5 mg/mg; <0.75 mg/mg, time to achieving CRR, and time to treatment failure. Safety was assessed through end-of-study., Results: Following enrolment challenges (COVID-19 pandemic; Ukraine/Russia crisis), the sponsor terminated the study early; 33 participants were randomized (placebo, n = 16; guselkumab, n = 17). At Week24, 56.3% (9/16) in the placebo group and 35.3% (6/17) in the guselkumab group achieved the primary end point. No apparent differences were observed in the secondary endpoints. Through end-of-study, 75% of placebo patients and 71% of guselkumab patients reported ≥1 adverse event; most were mild-to-moderate severity., Conclusion: Guselkumab+background therapy did not demonstrate superior reduction in proteinuria vs placebo+background in this small cohort of patients with active LN. Safety results were consistent with the known safety profile of guselkumab., Trial Registration: clinicaltrials.gov: NCT04376827., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology.)

Published
2024
Full Text
View/download PDF

47. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.

Author

Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Han J, and Taylor P

Subjects
Antibodies, Monoclonal administration & dosage, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid immunology, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Injections, Intravenous, Male, Methotrexate therapeutic use, Middle Aged, Patient Selection, Placebos, Safety, Treatment Outcome, Antibodies, Monoclonal therapeutic use, Arthritis, Rheumatoid drug therapy, Tumor Necrosis Factor-alpha immunology
Abstract

Objective: To assess the efficacy and safety of intravenous administration of golimumab in patients with rheumatoid arthritis (RA)., Methods: Adult patients with RA in whom disease activity was persistent despite treatment with methotrexate (MTX) at a dosage of 15-25 mg/week for > or = 4 weeks were randomized to receive intravenous infusions of placebo plus MTX or intravenous infusions of golimumab at a dose of 2 mg/kg or 4 mg/kg, with or without MTX, every 12 weeks through week 48. Patients with <20% improvement in the swollen and tender joint counts could enter early escape and receive additional active treatment (week 16) or could have their dose regimen adjusted (week 24). The primary end point was the proportion of patients achieving a 50% response according to the American College of Rheumatology improvement criteria (ACR50) at week 14., Results: The primary study end point was not met (at week 14, an ACR50 response was observed in 21% of the patients treated with golimumab plus MTX compared with 13% of the patients treated with placebo plus MTX [P = 0.051]). By week 24, significantly more patients treated with golimumab plus MTX had achieved an ACR50 response. Differences in the proportion of patients achieving an ACR50 response between the group receiving golimumab monotherapy and the group receiving placebo plus MTX were not significant at either week 14 (16% versus 13%) or week 24 (10% versus 9%). At week 48, the proportions of patients achieving ACR20 and ACR50 responses were highest among those who had received golimumab 4 mg/kg plus MTX (70% and 48%, respectively). Concomitant treatment with MTX was associated with a lower incidence of antibodies to golimumab. The most commonly reported adverse events through week 48 were infections (48% of patients treated with golimumab with or without MTX and 41% of patients receiving placebo plus MTX)., Conclusion: The primary end point was not met. However, intravenously administered golimumab plus MTX appears to have benefit in the longer-term reduction of RA signs/symptoms in MTX-resistant patients, with no unexpected safety concerns.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results